The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...

Full description

Bibliographic Details
Main Authors: Sijia Ren, Xinxin Xiong, Hua You, Jianfei Shen, Penghui Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
NSCLC
immunotherapy
immune checkpoint blockade
angiogenesis inhibitors
combination therapy
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.689132/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.689132/full

Similar Items